TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25225285

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg bid for 24 weeks (Group A)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg bid for 4 weeks, then 150 mg qd (Group B)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 323
Study: 23207783

Group type: EXPERIMENTAL
Intervention: Korean hand acupuncture (KHA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham KHA
Number of subjects: 42
Study: 19968158

Group type: EXPERIMENTAL
Intervention: Closed haemorrhoidectomy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Open haemorrhoidectomy
Number of subjects: 56
Study: 17727588

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with music (12 weeks)
Number of subjects: 365
Study: 15014210

Group type: EXPERIMENTAL
Intervention: Atrial prevention and termination therapies ON (n = 199)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Atrial prevention and termination therapies OFF (n = 206)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Atrial prevention and termination therapies ON (subgroup of 192 patients with a history of ATA's)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Atrial prevention and termination therapies OFF (subgroup of 192 patients with a history of ATA's)
Number of subjects: 451
Study: 12503233

Group type: EXPERIMENTAL
Intervention: SC's nutrition program
Number of subjects: 238

Group type: COMPARATOR
Intervention: Comparison children
Number of subjects: 238
Study: 9834044

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study: 8077888

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 36
Study: 2589002

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 60
Study: 815188

Group type: EXPERIMENTAL
Intervention: Paracetamol plus codeine (P + C) 350 + 20 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 500 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30862526

Group type: EXPERIMENTAL
Intervention: Non-periodized resistance training (NP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Daily undulating periodization resistance training (DUP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study: 29162132

Group type: EXPERIMENTAL
Intervention: High-level MAP (90-100 mmHg)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Low-level MAP (60-70 mmHg)
Number of subjects: 322
Study: 25415247

Group type: EXPERIMENTAL
Intervention: Combination 70% mineralized: 30% demineralized FDBA
Number of subjects: 42

Group type: COMPARATOR
Intervention: 100% mineralized FDBA
Number of subjects: 42
Study: 23489754

Group type: EXPERIMENTAL
Intervention: Minocycline pleurodesis (300 mg)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 214
Study: 21619621

Group type: EXPERIMENTAL
Intervention: Full-serve evidence service (database access, monthly e-mail alerts, and full-text article availability)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Self-serve evidence service (database access only)
Number of subjects: 168
Study: 18028181

Group type: EXPERIMENTAL
Intervention: Rate control strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rhythm control strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blockers of the renin angiotensin system and statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial specific antiarrhythmic drugs and direct thrombin inhibitors
Number of subjects: 0
Study: 15800330

Group type: EXPERIMENTAL
Intervention: Supervised home‐based flexible training program (14 weeks)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 111
Study: 12354317

Group type: EXPERIMENTAL
Intervention: Withdrawal of long-term antipsychotic medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9872197

Group type: EXPERIMENTAL
Intervention: Albuterol treatment (n=8)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo treatment (n=7)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Overall prevalence of EIB in athletes
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: EIB prevalence by race
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Demographic associations with EIB
Number of subjects: 238
Study: 7625335

Group type: EXPERIMENTAL
Intervention: Inversion Recovery (IR) method
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Spin Echo method
Number of subjects: 158

Group type: COMPARATOR
Intervention: Comparison of IR and Spin Echo
Number of subjects: 158
Study: 2750674

Group type: EXPERIMENTAL
Intervention: High-dose heparin (12,500 U subcutaneously every 12 hours for 10 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-dose heparin (5,000 U subcutaneously every 12 hours for 10 days)
Number of subjects: 100
Study: 319692

Group type: EXPERIMENTAL
Intervention: Caffeine; specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal children); specific details not mentioned
Number of subjects: 0
Study: 31899035

Group type: EXPERIMENTAL
Intervention: Untreated neovascular age‐related macular degeneration (nAMD)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Geographic atrophy (GA) in the fellow eye
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Higher 52‐single nucleotide polymorphism AMD genetic risk score
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: SNPs at CFH, ARMS2, or C3
Number of subjects: 627
Study: 31255449

Group type: EXPERIMENTAL
Intervention: AeRop exercise
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no AeRop exercise)
Number of subjects: 64
Study: 27995939

Group type: EXPERIMENTAL
Intervention: Telephone-based management (weekly advice by telephone for 12 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Telephone-based management
Number of subjects: 120
Study: 25819700

Group type: EXPERIMENTAL
Intervention: Naltrexone (starting dose of 6.25mg, followed by long-acting injectable naltrexone)
Number of subjects: 6
Study: 24355949

Group type: EXPERIMENTAL
Intervention: 10% Lippia sidoides (LS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine digluconate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Distilled water (negative control)
Number of subjects: 10
Study: 22000810

Group type: EXPERIMENTAL
Intervention: Panitumumab 6 mg/kg + FOLFIRI every 2 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Panitumumab 9 mg/kg + irinotecan every 3 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Panitumumab (both dosages)
Number of subjects: 95
Study: 17628656

Group type: EXPERIMENTAL
Intervention: Right visual field presentation of stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased demands on verbal working memory via a secondary task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased demands on spatial working memory via a secondary task
Number of subjects: 0
Study: 16563893

Group type: EXPERIMENTAL
Intervention: Return to normal activities at 2 weeks after AMI
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation and return to normal activities at 6 weeks after AMI
Number of subjects: 142
Study: 15145000

Group type: EXPERIMENTAL
Intervention: Symmetry Aortic Connector (Group I, n = 39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional handsewn anastomosis (Group II, n = 38)
Number of subjects: 77
Study: 12397461

Group type: EXPERIMENTAL
Intervention: SCAC (scatter correction and attenuation correction)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Uncorrected images
Number of subjects: 142

Group type: COMPARATOR
Intervention: CAG (coronary angiography)
Number of subjects: 142
Study: 9617707

Group type: EXPERIMENTAL
Intervention: Good repositioning quality
Number of subjects: 9

Group type: COMPARATOR
Intervention: Poor repositioning quality
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intra-observer variability
Number of subjects: 9
Study: 7659631

Group type: EXPERIMENTAL
Intervention: Content plus instruction on their own breasts
Number of subjects: 614

Group type: COMPARATOR
Intervention: Content plus supervised practice on a model with implanted lumps
Number of subjects: 614

Group type: COMPARATOR
Intervention: Content only
Number of subjects: 614
Study: 2714088

Group type: EXPERIMENTAL
Intervention: Lamicel (synthetic polyvinyl sponge with magnesium sulphate)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Synthetic tent without magnesium sulphate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (40 patients)
Number of subjects: 41
Study: 328243

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 58
Study: 31099387

Group type: EXPERIMENTAL
Intervention: Losartan + Amlodipine (L/A)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Losartan + Hydrochlorothiazide (L/H)
Number of subjects: 231
Study: 27869476

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to maxillary incisors with a dose of 2 J/point, starting immediately after archwire insertion and repeated on specific days until the end of the leveling and alignment stage.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no LLLT treatment).
Number of subjects: 26
Study: 25814264

Group type: EXPERIMENTAL
Intervention: Outreach intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 420
Study: 23519634

Group type: EXPERIMENTAL
Intervention: Sugammadex (SUG group, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neostigmine plus atropine (NEO group, n=20)
Number of subjects: 40
Study: 21725872

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines
Number of subjects: 300000000
Study: 19135563

Group type: EXPERIMENTAL
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 480

Group type: COMPARATOR
Intervention: 400 mcg oral misoprostol
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Both sublingual and oral misoprostol
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 480
Study: 17306999

Group type: EXPERIMENTAL
Intervention: Pulsed mode delivery
Number of subjects: 138

Group type: COMPARATOR
Intervention: Near-continuous mode delivery
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138
Study: 15300958

Group type: EXPERIMENTAL
Intervention: clopidogrel/ASA combination
Number of subjects: 12562

Group type: COMPARATOR
Intervention: ASA
Number of subjects: 12562
Study: 11395702

Group type: EXPERIMENTAL
Intervention: Nickel-titanium alloys
Number of subjects: 0
Study: 9737514

Group type: EXPERIMENTAL
Intervention: Atrioventricular junction ablation and VVIR pacemaker (Abl+Pm)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pharmacological treatment (drug)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 7943694

Group type: EXPERIMENTAL
Intervention: Propofol/oxygen/nitrous oxide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enflurane/oxygen/nitrous oxide
Number of subjects: 20
Study: 3361324

Group type: EXPERIMENTAL
Intervention: Heparin subcutaneously three times daily (doses adjusted based on APTT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Heparin plus 0.5 mg dihydroergotamine twice daily (fixed dose of 5,000 IU heparin)
Number of subjects: 102
Study: 30698114

Group type: EXPERIMENTAL
Intervention: Switch from escitalopram to nortriptyline (n = 36)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Switch from nortriptyline to escitalopram (n = 72)
Number of subjects: 811
Study: 30419597

Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban (35-42 days)
Number of subjects: 7513

Group type: COMPARATOR
Intervention: Enoxaparin (10 ± 4 days)
Number of subjects: 7513

Group type: EXPERIMENTAL
Intervention: Asymptomatic DVT
Number of subjects: 7513

Group type: COMPARATOR
Intervention: No DVT
Number of subjects: 7513
Study: 27169641

Group type: EXPERIMENTAL
Intervention: Action plans
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Coping plans
Number of subjects: 400
Study: 25262178

Group type: EXPERIMENTAL
Intervention: VPA + DM60 (60 mg/day)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: VPA + DM30 (30 mg/day)
Number of subjects: 309

Group type: COMPARATOR
Intervention: VPA + Placebo
Number of subjects: 309
Study: 22931457

Group type: EXPERIMENTAL
Intervention: Healthy eating knowledge assessment through focus group interviews
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Focus group discussions on barriers to healthy eating
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Qualitative data collection and analysis
Number of subjects: 103
Study: 20212496

Group type: EXPERIMENTAL
Intervention: Taranabant 0.5 mg
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Taranabant 1 mg
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Taranabant 2 mg
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 18069576

Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril and indapamide
Number of subjects: 5569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5569
Study: 16473748

Group type: EXPERIMENTAL
Intervention: Topical wheatgrass cream applied twice daily for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 6 weeks
Number of subjects: 80
Study: 12395691

Group type: EXPERIMENTAL
Intervention: Antidepressants (specific types not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative meta-analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled analysis of original data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical methods
Number of subjects: 0
Study: 9452324

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study: 7842184

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nasal occlusion
Number of subjects: 12
Study: 2270546

Group type: EXPERIMENTAL
Intervention: Indomethacin (3% age oily solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorphenol‐camphor‐menthol‐solution (ChKM) with procain on gauze strip
Number of subjects: 0
Study: 366141

Group type: EXPERIMENTAL
Intervention: Continuous treatment of levamisole (150 mg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent treatment of levamisole (3 days per week, 150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly treatment of levamisole (150 mg one day per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular control of white blood cell counts 10 hours after intake of levamisole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term use of levamisole in RA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed treatment scheme of one single weekly dose of 150 mg
Number of subjects: 0
Study: 30784667

Group type: EXPERIMENTAL
Intervention: Long-term dual antiplatelet therapy (DAPT) in non-high bleeding risk (HBR) patients
Number of subjects: 3118

Group type: EXPERIMENTAL
Intervention: Long-term dual antiplatelet therapy (DAPT)
Number of subjects: 3118

Group type: COMPARATOR
Intervention: Short-term dual antiplatelet therapy (DAPT)
Number of subjects: 3118
Study: 28242304

Group type: EXPERIMENTAL
Intervention: Structured patient education (12-hour training manual)
Number of subjects: 315
Study: 26452168

Group type: EXPERIMENTAL
Intervention: Bedroom ventilation with window open (average CO2 level 660 ppm)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bedroom ventilation with inaudible fan disabled (average CO2 level 2395 ppm)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bedroom ventilation with inaudible fan operated (average CO2 level 835 ppm)
Number of subjects: 30
Study: 25052361

Group type: EXPERIMENTAL
Intervention: Medication optimization at discharge (ACEI or ARB, β-blocker, MRA, diuretics)
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: Specific treatment procedures beyond pharmacotherapy
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: Mortality and rehospitalization rates after 1 year
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: NYHA class status after 1 year
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: General health status improvement after 1 year
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: Medication adherence after 1 year
Number of subjects: 1853
Study: 22399699

Group type: EXPERIMENTAL
Intervention: Twice-a-week supervised aerobic and resistance training plus exercise counseling
Number of subjects: 606

Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 606
Study: 19631844

Group type: EXPERIMENTAL
Intervention: Various restorative treatments
Number of subjects: 0
Study: 17049818

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone (50 mg/14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 0
Study: 16316360

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16409880

Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus oral nutritional supplements (360 ml of 1.5 kcal/ml, 20 g of protein per day) until hospital discharge
Number of subjects: 5033

Group type: EXPERIMENTAL
Intervention: Early tube feeding
Number of subjects: 5033

Group type: EXPERIMENTAL
Intervention: Enteral tube feeding via PEG
Number of subjects: 5033

Group type: COMPARATOR
Intervention: Enteral tube feeding via NG
Number of subjects: 5033
Study: 10826395

Group type: EXPERIMENTAL
Intervention: ACE‐I (delapril)
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Ca‐antagonist (manidipine)
Number of subjects: 1748
Study: 8651166

Group type: EXPERIMENTAL
Intervention: Rennie Liquid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maalox Liquid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1813613

Group type: EXPERIMENTAL
Intervention: Amantadine (dopamine agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine (tricyclic antidepressant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6689226

Group type: EXPERIMENTAL
Intervention: Gentamicin from the same lot number (Group I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gentamicin from different lot numbers (Group II)
Number of subjects: 20
Study: 30132265

Group type: EXPERIMENTAL
Intervention: Fatigue-related educational program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 29762253

Group type: EXPERIMENTAL
Intervention: Continuous exercise training (CONT) for 60 min·d at 70% HRpeak
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interval exercise training (INT) for 60 min·d (90% HRpeak for 3 min and 50% HRpeak for 3 min)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both CONT and INT training
Number of subjects: 31
Study: 26409098

Group type: EXPERIMENTAL
Intervention: ProMRI pacemaker system
Number of subjects: 245
Study: 25500229

Group type: EXPERIMENTAL
Intervention: Localized high-frequency source ablation (HFSA)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (CPVI)
Number of subjects: 232

Group type: COMPARATOR
Intervention: CPVI + HFSA
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: HFSA
Number of subjects: 232
Study: 22744994

Group type: EXPERIMENTAL
Intervention: Traditional PR plus harmonica playing (HT; n = 9)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional PR (C; n = 16)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined sample (both groups)
Number of subjects: 28
Study: 20604702

Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling (TMC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone Monitoring (TM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 19030754

Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 60
Study: 15515153

Group type: COMPARATOR
Intervention: Individual treatments compared to control
Number of subjects: 0
Study: 12963896

Group type: EXPERIMENTAL
Intervention: Combination therapy with a topical retinoid (e.g., adapalene) and an antibiotic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical retinoids alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical or oral antibiotics
Number of subjects: 0
Study: 10235199

Group type: EXPERIMENTAL
Intervention: Domperidone 2 x 10‐mg tablets 4 times daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Metoclopramide 1 x 10‐mg tablet + 1 placebo tablet 4 times daily
Number of subjects: 93
Study: 9094866

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 177

Group type: COMPARATOR
Intervention: Non-antibiotics
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Bactibilia
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sterile bile
Number of subjects: 177
Study: 1811441

Group type: EXPERIMENTAL
Intervention: Improved ORS formulation (maltodextrin 20 g, glycine 4 g, glycyl-glycine 4 g)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard ORS (WHO formulation containing citrate)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Improved ORS formulation
Number of subjects: 108
Study: 31505228

Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260